EPAC-Specific Inhibitors via Ribose Substituent Modification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmacological therapeutics lack effective methods for selectively modulating Exchange Protein Activated by cAMP (EPAC) 1 and EPAC2, which are crucial in various biological processes and implicated in diseases such as cancer, diabetes, and neurological disorders, with limited specific antagonists available.
Innovation Solution
Development of a high-throughput screening assay for identifying EPAC-specific inhibitors and synthesis of chemical analogs that selectively block biochemical and cellular cAMP-induced EPAC activation, providing potent EPAC inhibition and improved pharmacological properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If existing pharmacological therapeutics target the cAMP signaling pathway, then multiple biological processes can be regulated, but selective modulation of EPAC1 and EPAC2 is insufficient
Solution Approach 1:
The patent modifies chemical parameters of cAMP analogs by introducing specific substituents (e.g., at positions 2', 3', 5' of the ribose ring) to change binding affinity and selectivity. This allows differentiation between EPAC1 and EPAC2 binding, achieving selective modulation while maintaining cAMP pathway targeting capability.
Solution Approach 2:
The invention introduces localized modifications at specific positions of the cAMP molecule (particularly the ribose substituents) to create region-specific interactions with EPAC proteins. This local quality change enables selective binding to EPAC1 or EPAC2 without affecting the overall cAMP signaling function.
2Adaptability or versatility
If only a few EPAC specific antagonists are available, then current therapeutics can be limited, but developing more requires complex chemical synthesis
Solution Approach 1:
The patent divides the cAMP molecule into functional segments (adenosine core, ribose, phosphate groups) and introduces substituents at specific segments. This segmentation approach allows systematic generation of multiple inhibitors by varying substituents at different positions, expanding the library of EPAC inhibitors through modular synthesis.
Solution Approach 2:
The invention creates a universal scaffold (modified cAMP core) that can bind to both EPAC1 and EPAC2, with specific substituents determining selectivity. This multi-functional scaffold approach allows a single synthetic methodology to generate multiple EPAC inhibitors with different specificities, reducing overall synthesis complexity.
3Reliability
If EPAC inhibitors are developed for disease treatment, then therapeutic potential increases, but pharmacological properties must be optimized
Solution Approach 1:
The patent systematically varies pharmacological parameters of the inhibitors including IC50 values, selectivity ratios, and cellular concentration requirements. By changing substituent parameters, the invention optimizes these pharmacological properties to achieve desired therapeutic effects while managing toxicity and pharmacokinetics.
Data Source
AI summary
Embodiments of the invention are directed to compounds that inhibit an activity of EP AC proteins and methods of using the same. The inventors have developed a sensitive and robust high throughput screening (HTS) assay for the purpose of identifying EPAC specific inhibitors (Tsalkova et al. (2012) PLOS ONE 7(1):e30441).